Repros Therapeutics Gets FDA OK For Phase 2b Trial of Proellex(R)-V

Repros Therapeutics Inc., located in The Woodlands, Texas, met with the FDA to discuss clinical development of Proellex-V (telapristone). Proellex-V is a product that is administered to the vagina to treat uterine fibroids.

http://bionews-tx.com/news/2013/05/24/repros-therapeutics-gets-fda-ok-for-phase-2b-trial-of-proellexr-v/

Repros Therapeutics’ Proellex Enters Breast Cancer Phase 2 Study in Collaboration With Northwestern University

Texas-based biotechnology company, Repros Therapeutics Inc, known for the development of small molecule drugs to manage issues of the female genital tract, has announced its collaboration with the Breast Cancer Program at the Robert H. Lurie Comprehensive Cancer Center and Feinberg School of Medicine.

http://bionews-tx.com/news/2013/04/30/repros-therapeutics-proellex-enters-breast-cancer-phase-2-study-in-collaboration-with-northwestern-university/

Woodlands-Based Repros Reports Issuance of Two Additional U.S. Androxal Patents

Woodlands-Based Repros Reports Issuance of Two Additional U.S. Androxal Patents

http://bionews-tx.com/news/2013/04/11/woodlands-based-repros-reports-issuance-of-two-additional-u-s-androxal-patents/

(AUA) Accepts Woodlands-Based Repros Therapeutics Inc.’s Androxal Versus Topical Gel Comparative Study for Podium Presentation at Annual Meeting

Read about how the (AUA) Accepts Woodlands-Based Repros Therapeutics Inc.’s Androxal Versus Topical Gel Comparative Study for Podium Presentation at Annual Meeting

http://bionews-tx.com/news/2013/03/25/aua-accepts-woodlands-based-repros-therapeutics-inc-s-androxal-versus-topical-gel-comparative-study-for-podium-presentation-at-annual-meeting/